Exenatide - Intarcia Therapeutics

Drug Profile

Exenatide - Intarcia Therapeutics

Alternative Names: Exenatide in DUROS®; Exenatide intravenous - Intarcia Therapeutics; Exenatide subcutaneous implant - Intarcia Therapeutics; Exendin-4; ITCA-650

Latest Information Update: 30 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Intarcia Therapeutics
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Preregistration Type 2 diabetes mellitus

Most Recent Events

  • 01 Oct 2017 Intarcia Therapeutics completes a phase IIIb trial for Type-2 diabetes mellitus (Adjunctive treatment) in USA (NCT02638805)
  • 28 Sep 2017 Intarcia receives complete response letter from the US FDA for exenatide implant for Type 2 diabetes
  • 15 Sep 2017 Interim efficacy and adverse events data from the phase III FREEDOM 3S trial in Type 2 diabetes released by Intarcia Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top